Flu Vaccine Disruption

US exclusion from WHO’s influenza surveillance network will complicate seasonal vaccine development for pharmaceutical companies. Strain selection will rely on less comprehensive data, potentially reducing vaccine effectiveness against dominant variants. Future flu seasons could become deadlier as a result, particularly for vulnerable populations like the elderly. American laboratories scrambled to develop workarounds throughout 2025 but faced significant obstacles to data access. Vaccine formulation becomes more guesswork than science. Winter illness rates may climb noticeably.